UBS Maintains Sell on Zimmer Biomet Holdings, Lowers Price Target to $107
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Sell rating on Zimmer Biomet Holdings (NYSE:ZBH) and lowers the price target from $112 to $107.
August 08, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Danielle Antalffy maintains a Sell rating on Zimmer Biomet Holdings and lowers the price target from $112 to $107.
The Sell rating and lowered price target from a major financial institution like UBS is likely to negatively impact investor sentiment and short-term stock price for Zimmer Biomet Holdings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100